Guardant Health AMEA

Join us for an insightful panel discussion on 6th March 2025, from 7:00-8:00 PM, as leading experts explore how Minimal Residual Disease (MRD) insights are transforming colorectal cancer management. Organized by Voice of Healthcare and powered by Zydus and Guardant, this session will dive into early detection, personalized treatment approaches, and the future of colorectal cancer care. Register Here For The Session: https://lnkd.in/gY-2j5qZ Meet The Speakers: Dr. Niti Raizada, Principal Director Medical Oncology, Fortis Healthcare, BG Road, Bengaluru Dr Vaibhav Choudhary, Consultant, Medical Oncology, Kokilaben Dhirubhai Ambani Hospital Dhirubhai Ambani Hospital and Medical Research Center, Mumbai Dr. Priya Tiwari, Head - Medical Oncology, Artemis Hospitals, Gurgaon Dr. Palanki Satya Dattatreya, Chief - Medical Oncologist, Department of Medical Oncology, RENOVA HOSPITALS, Hyderabad Moderator Dr Manisha Khurana, Founder - Next Edge and Editor in Chief – Voice of Healthcare Zydus Group Guardant Health #ColorectalCancer #MRDInsights #CancerCare #Oncology #ZydusLifesciences #GuardantHealth

Guardant Health stands with all who are affected by colorectal cancer. The opportunity to give everyone more time free from cancer inspires us to transform cancer care with advanced blood and tissue tests, and the data they unlock across the continuum. Early detection matters. When caught early, colorectal cancer is highly treatable, yet it remains the second leading cause of cancer-related deaths worldwide. Get screened. Encourage loved ones to do the same. Early detection saves lives ??. #ColorectalCancerAwareness #ScreeningSavesLives #EarlyDetection Reference: Colorectal Cancer. World Health Organization. Last Accessed Feb 2025.?https://lnkd.in/eJa4TKhv.

Calling all oncologists! Join us on March 4th from 7.30pm to 8.45pm (GMT+8) for a webinar discussion entitled “MRD Roundtable: Enhancing patient outcomes through minimal residual disease detection and surveillance monitoring”. Register for this webinar today at https://lnkd.in/gjQVZN2M This webinar will feature leading medical oncologists such as Dr. Freddy Huang from Taiwan and Dr. Arthur Lui from Philippines.?The session will be moderated by Dr. Suyog Jain M.D. from Guardant Health AMEA. We look forward to your participation in this webinar. Speak to your doctor today about minimal residual disease (MRD) testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC?to find out more about our MRD test which can help oncologists identify patients at a higher risk of recurrence. This test is for prescription use only. #guardanthealth #guardanthealthamea #webinar #MRD #minimalresidualdisease #surveillancemonitoring #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

Guardant Health and Zydus Lifesciences announced our support for the newly launched Liquid is Solid? (LiS) Academy’s educational effort. Established and driven by leading oncologists, the LiS academy is an independent academic forum and a first-of-its-kind initiative in India, which is focused on increasing the awareness of precision medicine using liquid biopsies (minimally invasive blood-based tests) in transforming cancer care. Learn more about this collaboration: https://lnkd.in/gKnFcSvj

February is Cancer Prevention Month. Screening for cancer is a form of secondary prevention aimed at reducing mortality rates without necessarily altering the incidence of the disease.1 By identifying premalignant lesions and intervening early in the carcinogenic process, screening can slow disease progression and facilitate early curative therapy when appropriate.1 Colorectal cancer (CRC), for example, is most treatable when detected early. Early stages disease has favourable prognosis with 5-year survival rate of 90% declining to 71% for stage III and 14% for advanced disease.2 Speak to your healthcare provider today about colorectal cancer screening and get up to date with screening with a simple blood draw. Visit us at https://lnkd.in/g82ScDHT to find out more about the Shield? blood test which is the first blood test to be approved by the US FDA as a primary screening option for CRC. References: 1. Moleyar-Narayana P, Leslie SW, Ranganathan S. Cancer Screening. [Updated 2024 May 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://lnkd.in/gjki6m9h 2. AlZaabi A, AlHarrasi A, AlMusalami A, et al. Early onset colorectal cancer: Challenges across the cancer care continuum. Ann Med Surg (Lond). 2022;82:104453. Published 2022 Aug 22. doi:10.1016/j.amsu.2022.104453 #guardanthealth #guardanthealthamea #shield #colorectalcancerscreening #screening #cancerpreventionmonth #precisiononcology #precisionmedicine #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

The World Cancer Day theme for 2025 to 2027, “United by Unique”, places patients at the heart of the cancer care journey. Guardant Health is improving patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant’s tests are transforming cancer care across all stages of the disease, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. On World Cancer Day, let’s stand united in our challenges and unique in our triumphs as we fight to conquer cancer with data. Visit us at https://lnkd.in/fyqKfNs to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #worldcancerday #unitedbyunique #precisiononcology #precisionmedicine #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

We have recently announced an agreement with the Abu Dhabi Public Health Centre to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield? test. https://lnkd.in/gVCfEMvi The agreement was set up through Hikma Pharmaceuticals PLC, a multinational pharmaceutical group and regional partner for Guardant in the Middle East and North Africa, and will be administered by the M42 Healthcare system.1 Colorectal cancer is the third most common type of cancer in Abu Dhabi, with 63% of cases diagnosed at a late stage, which adversely affects health outcomes and lowers survival rates.2?The introduction of the Shield blood test is intended to be a significant step forward in improving screening participation, early detection and outcomes for the community. Visit us at https://lnkd.in/g82ScDHT to find out more about the Shield blood test. Speak to your doctor today about colorectal cancer screening with a simple blood draw. References 1.?Abu Dhabi Public Health Centre press release:https://lnkd.in/grP-9vy7 2.?BMC Public Health. 2023 Oct 16; 23:2015. doi:10.1186/s12889-023-16951-7 #guardanthealth #guardanthealthamea #hikma #M42 #cancerscreening #shield #colorectalcancer #CRC #pressrelease #news #precisiononcology #precisionmedicine #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

Happy Lunar New Year! - from all of us at Guardant Health. Visit us at https://lnkd.in/fyqKfNs to find out more.

Sharing insights from a recently published biopharma whitepaper, here are some key reasons to include China in oncology drug development globally. With over 4.8 million cases in 2022 alone, China has a high and rising cancer incidence rate and China accounts for 24% of new cancer cases worldwide as nearly one out of four new cancer cases globally are from China. The China National Medical Products Administration (NMPA) guidelines require local Chinese patients to be included in clinical trials. With over 4,300 clinical trial registrations in 2023, China is a strong base for clinical trials globally. Lastly, China has also overtaken U.S. to become the number one destination for precision oncology drug studies in 2023 with 1,892 trials in China compared to 1,134 in the U.S. Download this whitepaper entitled “Precision Oncology Drug Development in China: Opportunities, Challenges, and Fast Paths Forward” to learn more about unlocking the potential of China’s biopharma market. https://lnkd.in/g5AfbRV5 . Contact our biopharma team at [email protected] to see how we can help you accelerate oncology clinical trials and bring the next generation of cancer therapies to patients sooner. Visit us at https://lnkd.in/fyqKfNs to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. Reference: Yang, Brian. Precision Oncology Drug Development in China: Opportunities, Challenges and Fast Paths Forward [White paper]. Pharma Ignite. 12 November 2024. #guardanthealth #guardanthealthamea #whitepaper #citeline #biopharma #CDx #companiondiagnostics #drugdevelopment #clinicaltrials #precisiononcology #oncologytrials #china #precisionmedicine #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

Check out this poster which will be presented at the 2025 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium entitled “Landscape of metastatic colorectal cancer (CRC) using comprehensive circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in India: Expanding beyond RAS and RAF”. This poster is one of several poster presentations by Guardant Health at the ASCO GI conference this year. Background of study: Traditional testing in metastatic colorectal cancer (mCRC) primarily focuses on RAS and RAF mutations. However, a broader range of emerging biomarkers, collectively termed the "Pressing panel"(PP), identifies patients with RAS/RAF wild-type tumors who may particularly benefit from anti-EGFR therapy. Comprehensive liquid biopsies provide a non-invasive method for identifying traditional and emerging biomarkers. Limited genomic data, including the prevalence of PP alterations (alts), is available for mCRC patients in India tested by ctDNA NGS. To find out the results of this study, attend the conference in person at the Moscone West Conference center in San Francisco, California from January 23rd to 25th or check out the abstract online during the conference: https://lnkd.in/gqTi3kpe. Congratulations to the authors of this study: Dr. Viraj Lavingia (Presenting author), Dr. Amit Rauthan, Dr. Nitesh Rohatgi, Dr. Ankur Bahl, Dr. Aparna Dhar, Dr. Atul Sharma, Dr. Bhuvan Chugh, Dr. Rejiv Rajendranath, Dr. Shekar Patil, Dr. Prabrajya Mohapatra, Dr. Vikas Ostwal, Rohit Bharat, Nippun Sandhir and Nisarg Joshi. Visit us at https://lnkd.in/fyqKfNs to learn more about our comprehensive genomic profiling tests, which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #ASCOGI #abstract #mCRC #colorectalcancer #cancerresearch #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #medicaloncologists